GTHP GUIDED THERAPEUTICS INC
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 924515 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY283.1%
TTM net income YoY-15.6%
TTM EPS YoY40.0%
Revenue 3-yr CAGR117.8%
Net income 3-yr CAGR—
Margins
Gross margin80.4%
Operating margin-304.0%
Net margin-446.2%
FCF margin—
EBITDA margin-302.5%
Returns
ROE—
ROA-267.0%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets546.1%
Debt / equity—
Current ratio0.11x
Interest coverage-3.31x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-128.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $767,000 | $7,000 | $98,000 | $13,000 | $81,000 |
| Cost of revenue | $196,000 | $5,000 | $62,000 | $81,000 | $61,000 |
| Gross profit | $571,000 | $2,000 | $36,000 | -$68,000 | $20,000 |
| R&D expense | $469,000 | $526,000 | $228,000 | $77,000 | $69,000 |
| SG&A expense | $2.31M | $1.30M | $3.00M | $3.01M | $2.17M |
| Operating income | -$2.37M | -$2.11M | -$3.46M | -$3.33M | -$2.36M |
| Interest expense | $617,000 | $381,000 | $278,000 | $582,000 | $1.15M |
| Pretax income | -$3.20M | -$2.42M | -$3.49M | -$4.34M | -$2.07M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.20M | -$2.42M | -$3.49M | -$4.34M | -$2.07M |
| EBITDA | -$2.36M | -$2.10M | -$3.45M | -$3.33M | -$2.36M |
| EPS (basic) | -0.04 | -0.05 | -0.07 | -0.15 | -0.18 |
| EPS (diluted) | -0.04 | -0.05 | -0.07 | -0.15 | -0.18 |
| Weighted avg. shares (diluted) | 78.41M | 57.34M | 51.13M | 32.51M | 13.38M |
| Balance sheet | |||||
| Cash & equivalents | $63,000 | $388,000 | $591,000 | $2.31M | $643,000 |
| Receivables | $4,000 | $3,000 | $7,000 | $6,000 | $46,000 |
| Inventory | $448,000 | $633,000 | $632,000 | $548,000 | $571,000 |
| Current assets | $605,000 | $1.20M | $1.39M | $3.00M | $1.64M |
| PP&E, net | $16,000 | $23,000 | $32,000 | $42,000 | $14,000 |
| Total assets | $1.32M | $1.38M | $1.67M | $3.37M | $2.04M |
| Current liabilities | $6.64M | $6.16M | $4.81M | $4.87M | $5.69M |
| Short-term debt | — | — | $0 | $17,000 | $88,000 |
| Long-term debt | — | — | — | $0 | $22,000 |
| Total debt | — | — | — | $17,000 | $110,000 |
| Total liabilities | $7.33M | $6.27M | $5.47M | $6.25M | $7.49M |
| Shareholders' equity | -$6.01M | -$4.89M | -$3.81M | -$2.88M | -$5.45M |
| Net debt | — | — | — | -$2.30M | -$533,000 |
| Shares outstanding | 86,154 | 65.13M | 54.10M | 48.60M | 13.67M |
| Cash flow statement | |||||
| Operating cash flow | -$1.07M | -$1.12M | -$1.75M | -$1.48M | -$1.59M |
| Capital expenditure | $2,000 | $0 | $0 | $31,000 | $14,000 |
| Free cash flow | -$1.07M | -$1.12M | -$1.75M | -$1.51M | -$1.61M |
| Investing cash flow | -$2,000 | $0 | — | -$31,000 | -$14,000 |
| Financing cash flow | $745,000 | $916,000 | $24,000 | $3.18M | $2.07M |
| Depreciation & amortization | $10,000 | $9,000 | $9,000 | $4,000 | $1,000 |
| Stock-based compensation | $377,000 | $120,000 | $1.81M | $1.38M | $228,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.